Skip to main content

Home/ Vitamin D/ Group items tagged epidemiological nutrition research prostate_cancer 2007 1.25(OH)2D

Rss Feed Group items tagged

Matti Narkia

Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25... - 0 views

  •  
    Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk.
    Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E.
    Prostate. 2007 Jun 15;67(9):911-23.
    PMID: 17440943
    DOI: 10.1002/pros.20570

    RESULTS
    No association was found between these SNPs or their associated haplotypes and all PC subtypes except that haplotype 2 (A-f-b) with Cdx2 A, Fok1 f, and Bsm1 b alleles and haplotype 3 (A-F-B) with Cdx2 A, Fok1 F and Bsm1 B alleles compared to the most common haplotype (A-F-b), were associated with reduced risk of aggressive PC (high stage or Gleason sum 7; P = 0.02), both with two alleles suspected of being low risk. Carriers of the variant Cdx2 A allele who were deficient in plasma 25-hydroxyvitamin D (15 ng/ml) compared to non-carriers with normal 25-hydroxyvitamin D, had a lower risk of total and poorly differentiated PCs (Gleason sum 7) (P for interaction = 0.02 and 0.04, respectively). Plasma 1,25-dihydroxyvitamin D deficiency (26 pg/ml) was associated with a threefold risk of poorly differentiated PC (P for interaction = 0.01) when comparing carriers of the Cdx2 A allele to non-carriers with normal 1,25-dihydroxyvitamin D.

    CONCLUSION
    In this population of men, none of the VDR polymorphisms studied was associated with susceptibility to PC.

    Carriers of the variant Cdx2 A allele with low plasma 25-hydroxyvitamin D may experience a reduction in risk of total and poorly differentiated prostate cancers compared to non-carriers with adequate 25-hydroxyvitamin D.
1 - 1 of 1
Showing 20 items per page